Identifying, treating and managing Hepatitis may not be as easy as 1, 2, 3; but testing can be.
Hepatitis remains a significant cause of morbidity and mortality worldwide. Accurate testing is necessary to make complex therapeutic decisions for hepatitis patients, minimizing treatment failure and resistance, and improving clinical outcomes.
With molecular assays to assess hepatitis viral load, antiviral resistance mutations, genotype and precore/core mutations—you can detect infections and modify treatment faster, when it matters most.
For immunocompromised patients, screening to identify the specific infection, treating effectively, and ongoing monitoring is the key to managing hepatitis.
|Hepatitis D Virus (HDV) IgM|
|Hepatitis D Virus (HDV) Total Antibody|
|Hepatitis E Virus (HEV) IgG|
|Hepatitis E Virus (HEV) IgM|
|Hepatitis E Virus (HEV) IgG, IgM Panel|
|Pathogen Load Monitoring||Hepatitis B Virus (HBV) Quantitative Real-time PCR|
|Hepatitis C Virus (HCV) Quantitative Real-time RT-PCR|
|Hepatitis E Virus (HEV) Quantitative Real-time RT-PCR|
|Antiviral Resistance Assessment||Hepatitis C Virus (HCV) NS3 Protease Drug Resistance|
|Pathogen Characterization||Hepatitis C Virus (HCV) Genotyping|
It is estimated that up to 1.4 million people in the U.S. have chronic Hepatitis B Virus (HBV); more than 700,000 will die from HBV-related liver disease a year. The total number of HBV infections in healthy individuals is decreasing, however, due to the vaccine and stringent guidelines for infants/children and healthcare workers to be vaccinated.
Comprehensive testing guides complex therapeutic decisions for chronic HBV patients by minimizing treatment failure and improving clinical outcomes. Viracor Eurofins offers the superior line probe assay (LiPA) method for the assessment of antiviral resistance mutations, genotype, and precore/core mutations. LiPA detects mixed infections much earlier than sequencing assays which enables clinicians to modify treatment protocols in a more effective timeframe.
Hepatitis C Virus is the #1 cause of liver transplants in the U.S., and the #1 cause of death in HIV patients. Viracor Eurofins offers quantitative Hepatitis C Virus (HCV) RNA viral load and genotype testing. Extensive genetic heterogeneity between the six major genotypes, and a propensity to mutate, makes assay design challenging. The assay design includes multiple targets to minimize the possibility of false negative results or underquantification due to sequence anomalies within an assay target.
The Viracor Eurofins quantitative HCV RNA assay provides an extremely wide assay range of 12 - 1e8 IU/mL, detects all six genotypes, and has been calibrated to the World Health Organization HCV standard to provide accurate and consistent assessment of viral load across the entire assay range. Results below 12 IU/mL are reported as "Detected <12 IU/mL." Genotypes affect antiviral treatment decisions, guide dosage & duration of treatment. Each Genotype may also have a number of subtypes, which can cause different responses to therapy. We test for all six subtypes.
Hepatitis D virus (HDV) is an incomplete RNA virus that requires the helper function of Hepatitis B virus (HBV) envelope proteins (HBSAg) to replicate. The presence of HDV antibodies indicates exposure to HDV, but does not distinguish acute or chronic HDV infection. Typically the disappearance of HDV antibodies is indicative of resolution of infection.
Hepatitis E Virus (HEV) is uncommon in the U.S. It is transmitted from oral exposure to HEV-contaminated fecal material. HEV is more prevalent in developing countries where clean water and sanitation are not commonplace. HEV antibody testing is important in cases where other hepatitis causes have been excluded, since HEV infection is clinically indistinguishable from other types of acute viral hepatitis. Presence of HEV IgG indicates current or previous HEV infection. HEV IgM antibodies are normally present 1-4 weeks post-infection.